BLM is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BLM status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

BLM is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain BLM status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [4].

BLM is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain BLM status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

BLM is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BLM is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BLM is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BLM is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BLM is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BLM is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BLM is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BLM is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BLM is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BLM status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

BLM is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BLM is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BLM is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

BLM is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BLM status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].